Table 2.

Correlation of immunosuppression due to a hemato-oncological disease and progress or distant organ metastasis.

Characteristic	Patients with immunosuppression due to hemato-oncological disease alone	All other patients	p
Progress
No	10 (58.8%)	123 (84.2%)	0.010
Yes	7 (41.2%)	23 (15.8%)
Distant organ metastasis
No	14 (82.4%)	144 (98.6%)	0.000
Yes	3 (17.6%)	2 (1.4%)
Immunosuppression due to solid cancer, medical immunosuppression
No	17 (85.0%)	117 (80.1%)	0.578
Yes	3 (15.0%)	29 (19.9%)
Mitotic count
Score 1 (0–9 mitoses per 10 HPF)	10 (58.8%)	68 (46.6%)	0.339
Score 2–3 (≥10 per 10 HPF)	7 (41.2%)	78 (53.4%)
PFS (in months) ± SD (range)	21 ± 26 (0–75)	21 ± 27 (0–156)	0.992
OS (in months) ± SD (range)	21 ± 22 (0–75)	25 ± 31 (0–156)	0.587

HPF, high-power fields; PFS, progression-free survival; OS, overall survival.